242 related articles for article (PubMed ID: 8658798)
1. Quadruple immunotherapy will promise excellent graft survival in cadaveric renal transplants using cardiac arrest donor grafts.
Hoshinaga K; Shiroki R; Higuchi T; Horiba Y; Yanaoka M; Naide Y
Transplant Proc; 1996 Jun; 28(3):1591-3. PubMed ID: 8658798
[No Abstract] [Full Text] [Related]
2. Quadruple immunosuppressive therapy with low-dose cyclosporine provides superior kidney transplant outcome using grafts of non-heart-beating uncontrolled cadavers.
Shiroki R; Hoshinaga K; Tsukiashi Y; Higuchi T; Izumitani M; Horiba M; Naide Y
Transplant Proc; 1997 Dec; 29(8):3571-3. PubMed ID: 9414841
[No Abstract] [Full Text] [Related]
3. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression.
Toda F; Tanabe K; Tokumoto T; Ishikawa N; Koga S; Ito S; Yagisawa T; Toma H
Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909
[No Abstract] [Full Text] [Related]
4. Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants.
Inoue S; Beck Y; Nagao T; Uchida H
Transplant Proc; 1994 Oct; 26(5):2571-3. PubMed ID: 7940795
[No Abstract] [Full Text] [Related]
5. Long-term outcome of cadaveric kidney grafts with triple drug therapy.
Amemiya H; Suzuki S; Hayashi R; Nakatani T
Transplant Proc; 1994 Aug; 26(4):2097-8. PubMed ID: 8066683
[No Abstract] [Full Text] [Related]
6. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
[No Abstract] [Full Text] [Related]
7. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression.
Tanabe K; Tokumoto T; Ishikawa N; Kanematsu A; Oshima T; Harano M; Inui M; Yagisawa T; Nakajima I; Fuchinoue S; Takahashi K; Toma H
Transplant Proc; 1999 Nov; 31(7):2877-9. PubMed ID: 10578323
[No Abstract] [Full Text] [Related]
8. Prospective randomized study of quadruple versus triple therapy in long-term kidney allografts.
Fruchaud G; Buisson C; Abbou C; Desvaux D; Baron C; Benmaadi A; Chopin D; Bourgeon B; Dahmane D; Rostoker G; Weil B; Lang P
Transplant Proc; 1996 Oct; 28(5):2819. PubMed ID: 8908077
[No Abstract] [Full Text] [Related]
9. Current advantage of FK 506 in cadaveric kidney transplantation.
Ciancio G; Rosen A; Loreto-Grand B; Burke G; Siquijor A; Luque C; Esquenazi V; Miller J
Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207
[No Abstract] [Full Text] [Related]
10. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
[No Abstract] [Full Text] [Related]
12. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
[No Abstract] [Full Text] [Related]
13. Causes of long-term renal allograft failure: no chronic rejection at three years.
Shen GK; Isenberg AL; Singh TP; Hahn A; Conti DJ
Transplant Proc; 1998 Jun; 30(4):1205-6. PubMed ID: 9636489
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
el-Ghoroury M; Hariharan S; Peddi VR; Munda R; Schroeder TJ; Demmy AM; Alexander JW; First MR
Transplant Proc; 1997; 29(1-2):649-51. PubMed ID: 9123461
[No Abstract] [Full Text] [Related]
15. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Guttmann RD; Flemming C
Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
[TBL] [Abstract][Full Text] [Related]
16. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
Kaden J; Strobelt V; May G
Transplant Proc; 1998 Dec; 30(8):4011-4. PubMed ID: 9865279
[No Abstract] [Full Text] [Related]
17. Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation.
Lee HA; Slapak M; Venkatraman G; Mason J; Digard N; Wise M
Transplant Proc; 1993 Aug; 25(4):2699-700. PubMed ID: 8356720
[No Abstract] [Full Text] [Related]
18. Prospective randomized comparison of quadruple vs triple therapy for first cadaver transplants with immediate function.
Johnson CP; Slakey DP; Callaluce RD; Browne BJ; Roza AM; Adams MB
Transplant Proc; 1993 Feb; 25(1 Pt 1):585-6. PubMed ID: 8438425
[No Abstract] [Full Text] [Related]
19. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
20. Advantages of mizoribine over azathioprine in combination therapy with cyclosporine for renal transplantation.
Mita K; Akiyama N; Nagao T; Sugimoto H; Inoue S; Osakabe T; Nakayama Y; Yokota K; Sato K; Uchida H
Transplant Proc; 1990 Aug; 22(4):1679-81. PubMed ID: 2202125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
